<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725439</url>
  </required_header>
  <id_info>
    <org_study_id>BT0700BEL001</org_study_id>
    <nct_id>NCT00725439</nct_id>
  </id_info>
  <brief_title>An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne</brief_title>
  <official_title>An Open Label Pilot Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment of Moderate to Severe Facial Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at a new oral drug to treat acne. All patients in the study will get&#xD;
      active drug, there is no placebo arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Facial Lesion Count</measure>
    <time_frame>Post 12 weeks treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talarozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talarozole</intervention_name>
    <description>Oral Dose 1.0 mg once daily</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Rambazole</other_name>
    <other_name>R115866</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subject&#xD;
&#xD;
          -  Presence of moderate to severe facial acne vulgaris: having a minimum of 15 papules&#xD;
             and/or pustules and at least 2 nodulocystic lesions&#xD;
&#xD;
          -  In good general health and free of any disease state or physical condition which, in&#xD;
             the investigator's opinion, might have impaired evaluation of acne or exposed the&#xD;
             subject to an unacceptable risk by trial participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with types of acne other than acne vulgaris&#xD;
&#xD;
          -  Significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic&#xD;
             pancreatitis, osteoporosis, or a history indicating adrenal cortex dysfunction or any&#xD;
             other serious disease (including cancer and subjects known to be HIV positive)&#xD;
&#xD;
          -  History of any malignancy in the past 5 years, except for adequately treated basal&#xD;
             cell carcinoma of the skin&#xD;
&#xD;
          -  History of heart failure, myocardial infarction within the past six months, cardiac&#xD;
             arrhythmia, or under treatment for heart disorders&#xD;
&#xD;
          -  Clinically significant abnormal ECG-intervals or morphology of the ECG; QT or QTc &gt;470&#xD;
             ms in females or &gt;450 ms in males&#xD;
&#xD;
          -  Use of vitamin A (&gt;1000 microgram/day), phenytoin, carbamazepine, warfarin,&#xD;
             rifampicin, tetracyclines, ketoconazole, itraconazole, astemizole, terfenadine,&#xD;
             cisapride, anti-psychotics, anti-depressants, lithium, antimalarials, alpha-blocking&#xD;
             drugs, angiotensin-converting enzyme inhibitors, cyclosporin A, glucocorticosteroids&#xD;
             and non-steroid anti-inflammatory drugs, non-potassium-sparing diuretics&#xD;
&#xD;
          -  Use of oral retinoids 6 months prior to Visit 1&#xD;
&#xD;
          -  Use of other oral/topical therapy for acne unless stopped at Visit 1&#xD;
&#xD;
          -  Use of ultraviolet light (including artificial UVA and UVB as well as excessive&#xD;
             natural sun exposure) unless stopped at Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. D. Roseeuw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Dermatology, University Hospital Brussel (UZ Brussel)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice in Dermatology</name>
      <address>
        <city>Vilvoorde</city>
        <zip>B-1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital, Dermatology</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>NL-3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>September 23, 2011</last_update_submitted>
  <last_update_submitted_qc>September 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>R 115866</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

